U.S. District Court Upholds Validity of CINVANTI® Patents

Core Viewpoint - The U.S. District Court for the District of Delaware ruled in favor of Heron Therapeutics in its patent litigation against Fresenius Kabi USA regarding the injectable emulsion CINVANTI® (aprepitant), affirming the validity of Heron's patents which expire in 2035 [1][2]. Group 1 - The court found that Fresenius' proposed generic product would infringe on Heron's U.S. Patent Nos. 9,561,229 and 9,974,794 [1][2]. - Heron plans to seek a court order to prevent Fresenius from launching its generic version of CINVANTI® until after the patents expire in 2035 [2]. - The litigation was initiated in July 2022 following Fresenius' submission of an Abbreviated New Drug Application to the FDA for a generic version of CINVANTI® [2]. Group 2 - Craig Collard, CEO of Heron, expressed satisfaction with the court's decision and emphasized the company's commitment to defending its patent estate [3]. - Heron Therapeutics is focused on developing and commercializing therapeutic innovations aimed at improving patient care, particularly in acute care and oncology [4].